Accelerated COVID-19 vaccine development: milestones, lessons, and prospects

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 2×

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897

First case of 2019 novel coronavirus in the United States

Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030

Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures

Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,975

mRNA vaccines — a new era in vaccinology

Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889

Effectiveness of COVID-19 vaccines against the B.1.617.2 variant

Bernal, J. L., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · doi:10.1101/2021.05.22.21257658 · Cited by 2,888 · cited 2×

Towards vaccine lifecycle management (VLM): A systematic literature review of the issues and challenges

Sanae, A., Aicha, S. S., Adiba, E. B. E. I., & Noredine, E. K. (2024) · International Journal of Production Research · doi:10.1080/00207543.2024.2329317 · Cited by 7

Engineered cell membrane-based nano therapies fight infectious diseases

Ma, J., Xie, Y., Teng, Z., Jiang, L., & Liu, G. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113884 · Cited by 8

A cross-sectional study confirms temporary post-COVID-19 vaccine menstrual irregularity and the associated physiological changes among vaccinated women in Jordan

Almomani, E. Y., Hajjo, R., Qablan, A. M., Sabbah, D. A., & Al-Momany, A. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1211283 · Cited by 8

Good Manufacturing Practices and Upscaling of mRNA Vaccine Production

Stamoula, Ε., Vavilis, T., Dardalas, I., & Papazisis, G. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch6 · Cited by 7

The future of climate health research: An urgent call for equitable action- and solution-oriented science

Garcia, E., Eckel, S. P., Silva, S. J., McConnell, R., Johnston, J., Sanders, K. T., Habre, R., & Baccarelli, A. (2024) · Environmental Epidemiology · doi:10.1097/ee9.0000000000000331 · Cited by 6

Comparable cellular and humoral immunity upon homologous and heterologous COVID-19 vaccination regimens in kidney transplant recipients

Körber, N., Holzmann‐Littig, C., Wilkens, G., Liao, B., Werz, M. L., Platen, L., Cheng, C., Tellenbach, M., Kappler, V., Lehner, V., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172477 · Cited by 6

The glycosaminoglycan-binding chemokine fragment CXCL9(74–103) reduces inflammation and tissue damage in mouse models of coronavirus infection

de Oliveira, V. L. S., Queiroz‐Junior, C. M., Hoorelbeke, D., Santos, F. R. D. S., Chaves, I. D. M., Teixeira, M. M., Russo, R. C., Proost, P., Costa, V. V., Struyf, S., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1378591 · Cited by 6

HIV/AIDS and COVID-19: Shared Lessons From 2 Pandemics

Fauci, A. S., & Folkers, G. K. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae585 · Cited by 8

Nanotechnology Assisted Strategies to Tackle COVID and Long-COVID

Aadil, K. R., Bhange, K., Mishra, G., Sahu, A., Sharma, S., Pandey, N., Mishra, Y. K., Kaushik, A. K., & Kumar, R. (2025) · BioNanoScience · doi:10.1007/s12668-025-01812-x · Cited by 7

Development of Methods to Produce SARS CoV‐2 Virus‐Like Particles at Scale

Edeling, M. A., Earnest, L., Montoya, J. C., Yap, A. H. Y., Mumford, J., Roberts, J., Wong, C. Y., Hans, D., Grima, J., Bisset, N., et al. (2025) · Biotechnology and Bioengineering · doi:10.1002/bit.28937 · Cited by 5

Modeling the impact of early vaccination in an influenza pandemic in the United States

Nguyễn, V. H., Crépey, P., Williams, B. A., Welch, V. L. L., Pivette, J. M., Jones, C. H., & True, J. M. (2025) · npj Vaccines · doi:10.1038/s41541-025-01081-5 · Cited by 6

Looking beyond the origin of SARS-CoV-2: Significant strategic aspects during the five-year journey of COVID-19 vaccine development

Chakraborty, C., Lo, Y.-H., Bhattacharya, M., Das, A., & Wen, Z. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102527 · Cited by 8

Longitudinal Dynamics of Cellular Responses in Recovered COVID-19 Patients

Cheng, M., Liu, H., Chao Hui, Z. H. O. U., Li, R.-T., Zheng, J., Qin, Y., Yang, N., Zhang, Y., Huang, J., Zhu, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.911859 · Cited by 6

Drug hypersensitivity, in vitro tools, biomarkers, and burden with COVID ‐19 vaccines

Palomares, F., Paris, J. L., Labella, M., Doña, I., Mayorga, C., & Torres, M. J. (2022) · Allergy · doi:10.1111/all.15461 · Cited by 6

Leveraging lessons learned from the COVID-19 pandemic for HIV

Calder, T., Tong, T., Hu, D. J., Kim, J. H., Kotloff, K. L., Koup, R. A., Marovich, M., McElrath, M. J., Read, S. W., Robb, M. L., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00175-8 · Cited by 6

Identifying priority challenges and solutions for COVID-19 vaccine delivery in low- and middle-income countries: A modified Delphi study

Ariyarajah, A., Berry, I., Haldane, V. E., Loutet, M. G., Salamanca‐Buentello, F., & Upshur, R. E. G. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000844 · Cited by 6

A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model

Ma, J., Liu, X., Zhou, M., Chen, P., Chen, R., Wang, J., Zhu, H., Wu, K., Ye, J., Zhang, Y., et al. (2023) · Journal of Virology · doi:10.1128/jvi.01684-22 · Cited by 6

YouTube and COVID-19 vaccines: A mini scoping review

Narayanan, S., & Basch, C. H. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2202091 · Cited by 6

Immune-Mediated Organ-Specific Reactions to COVID-19 Vaccines: A Retrospective Descriptive Study

Ruiz-Fernández, C., de la Cámara, R. C., Martín-López, S., Guijarro, J., Huertas, A. L. G. D. L., Urroz, M., Miguel‐Berenguel, L., González-Muñoz, M., & Ramı́rez, E. (2023) · Pharmaceuticals · doi:10.3390/ph16050720 · Cited by 6

Timeline kinetics of protective immunity to SARS-CoV-2 upon primary vaccination and humoral response to variants after booster dose

Gouvea, M. D. P. G., Machado, K. L. L. L., de Oliveira, Y. G. P., Moulaz, I. R., Henriques, A. G., Gouveia, T. M., Thompson, B. P., Lança, K. E. M., Ramos, S. D. S., Lacerda, G. C. C., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.08.022 · Cited by 6

Digital Technologies and COVID-19 Vaccine Acceptance: Evidence From France and South Africa

Wamba, S., Guthrie, C., Queiroz, M., & Twinomurinzi, H. (2023) · Journal of Global Information Management · doi:10.4018/jgim.333611 · Cited by 4

COVID-19 Testing Among People with HIV: A Population Level Analysis Based on Statewide Data in South Carolina

Shi, F., Zhang, J., Yang, X., Gao, H., Chen, S., Weissman, S., Olatosi, B., & Li, X. (2023) · AIDS and Behavior · doi:10.1007/s10461-023-04244-4 · Cited by 6

Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model

Abdoli, A., Jamshidi, H., Taqavian, M., Baghal, M. L., & Jalili, H. (2024) · Scientific Reports · doi:10.1038/s41598-023-50822-w · Cited by 7

Project lightspeed: A case study in research ethics and accelerated vaccine development

Leisinger, K. M., & Schroeder, D. (2024) · Research Ethics · doi:10.1177/17470161241251597 · Cited by 6

COVID-19 Vaccine-Associated Transient Global Amnesia: A Disproportionality Analysis of the WHO Safety Database

Merino, D., Gérard, A. O., Obberghen, E. K. V., Ben-Othman, N., Ettore, É., Giordana, B., Viard, D., Rocher, F., Destère, A., Benoît, M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.909412 · Cited by 6

Comparison of IgA, IgG and neutralizing antibody responses following immunization with Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm’s COVID-19 vaccines.Preprint

Adjobimey, T., Meyer, J., Sollberg, L., Bawolt, M., Berens, C., Kovačević, P., Trudić, A., Parčina, M., & Hoerauf, A. M. (2021) · Research Square · doi:10.21203/rs.3.rs-1197023/v1 · Cited by 6

Germinal Center Response to mRNA Vaccination and Impact of Immunological Imprinting on Subsequent Vaccination

Kim, W. (2024) · Immune Network · doi:10.4110/in.2024.24.e28 · Cited by 5

An analysis of the waning effect of COVID-19 vaccinations

Lee, B., Song, H., Apio, C., Han, K., Park, J., Liu, Z., Xuwen, H., & Park, T. (2023) · Genomics & Informatics · doi:10.5808/gi.23088 · Cited by 5

Ethical and informative trials: How the COVID-19 experience can help to improve clinical trial design

Law, E., & Smith, I. (2024) · Research Ethics · doi:10.1177/17470161241261768 · Cited by 5

Case report: subacute thyroiditis after receiving SARS-CoV-2 vaccine, maybe not only adjuvants

Huang, Y., Chen, X., Wang, Q., Lei, X., & Zhang, L. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.856572 · Cited by 5

The research foundation for COVID-19 vaccine development

Messan, K. S., Sulima, P. P., Ghosh, D., & Nye, J. (2023) · Frontiers in Research Metrics and Analytics · doi:10.3389/frma.2023.1078971 · Cited by 5

Identification of HLA-A*24:02-Restricted CTL Candidate Epitopes Derived from the Nonstructural Polyprotein 1a of SARS-CoV-2 and Analysis of Their Conservation Using the Mutation Database of SARS-CoV-2 Variants

Takagi, A., & Matsui, M. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01659-21 · Cited by 5

Factors Affecting the Public Intention to Repeat the COVID-19 Vaccination: Implications for Vaccine Communication

Lee, Y., Park, K., Shin, J. H., Oh, J., Jang, Y., & You, M. (2023) · Healthcare · doi:10.3390/healthcare11091235 · Cited by 5

Association between receiving Covid‐19 vaccine and menstrual cycle patterns among childbearing women: A cross‐sectional study

AlRawi, H. Z., AlQurashi, A., AlDahan, D., Alkhudhayri, M., Alsharidah, A. R., Wani, T. A., & Al‐Jaroudi, D. (2024) · Health Science Reports · doi:10.1002/hsr2.1934 · Cited by 5

Assay for rapid quantification of capped and tailed intact mRNA

Gao, R. Y., Hu, T., Taylor, A. W., Lacey, R., Thomas, K. N., McCormick, C., Miller, D. F., Rowlen, K. L., & Dawson, E. D. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127339 · Cited by 4

Systemic and mucosal immune signatures of protection against SARS-CoV-2 transmission in humans

Rojo-Fernandez, A., Aslam, S., Alam, F., Escalera, A., Villamandos, V., Caton, B., Megías, G., Gonzalez, A., Buzón, L., Ayllón, J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102505 · Cited by 5

Intention to participate in COVID-19 vaccine clinical trials in May 2021: a cross-sectional survey in the general French population

Gagneux‐Brunon, A., Ward, J. K., Bonneton, M., Verger, P., Launay, O., & Botelho-Nevers, É. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2072630 · Cited by 4

Algorithms of Behavior and Behavior of Algorithms: A Conversation between Ashish Jha and Patrick Whitney

Park, M. S., Fahn‐Lai, P., Shukla, R., Nogueira, A., & Whitney, P. (2022) · She ji · doi:10.1016/j.sheji.2022.11.004 · Cited by 4

Effect of COVID-19 Vaccination on Menstrual Cycle Patterns of Reproductive-age Women: A Multi-centric Observational Study

Kumar, N., Gangane, N., Mohapatra, I., Rukadikar, C. A., Sharmila, V., Pushpalatha, K., Eerike, M., Santhoshi, G., Samantaray, S. R., Seth, S., et al. (2023) · Current Drug Research Reviews · doi:10.2174/2589977515666230608140606 · Cited by 9

Psychosocial Factors Inhibiting Timely COVID-19 Vaccination and Booster Receipt Among Transgender and Gender Diverse Adults

Smout, S. A., Guidry, J. P. D., & Benotsch, E. G. (2023) · Transgender Health · doi:10.1089/trgh.2023.0032 · Cited by 4

False positive serology of prepandemic chagasic samples with SARS‐CoV ‐2 antigen

Zuluaga, J. D. H., Santos‐Barbosa, J. C., Cuéllar, A., Puerta, C. J., & González, J. M. (2022) · Tropical Medicine & International Health · doi:10.1111/tmi.13818 · Cited by 4

Treating COVID-19: Targeting the Host Response, Not the Virus

Fedson, D. S. (2023) · Life · doi:10.3390/life13030712 · Cited by 4

The COVID-19 vaccine on Facebook: A study of emotions expressed by the Brazilian public

de Oliveira, G. F., Massarani, L., de Oliveira, T. M., Scalfi, G., & dos Santos, M. A. (2023) · Comunicar · doi:10.3916/c76-2023-10 · Cited by 4

Effectiveness of COVID-19 vaccines in Ecuador: A test-negative design

Pérez‐Tasigchana, R. F., Valcárcel-Pérez, I., Arias-Quispe, M., Astudillo, L., Bruno, A., Marco Herrera, G., Armas-González, R., de Mora, D., Pinos, J., Olmedo, A., et al. (2023) · Vaccine X · doi:10.1016/j.jvacx.2023.100404 · Cited by 6

The Effectiveness of the Third Dose of COVID-19 Vaccine: When Should It Be Performed?

Biganzoli, G., Mendola, M., Perrone, P. M., Antonangeli, L. M., Longo, A. B. E., Carrer, P., Colosio, C., Consonni, D., Marano, G., Boracchi, P., et al. (2024) · Vaccines · doi:10.3390/vaccines12030315 · Cited by 4

Impact of inactivated COVID-19 vaccines on viral shedding in B.1.617.2 (Delta) variant-infected patients

Hu, Z., Yin, Y. B., Wang, K., Xu, M., Ding, C., Song, Y., Yi, C., Li, J., Yi, Y., & Peng, Z. (2022) · Science China Life Sciences · doi:10.1007/s11427-021-2115-7 · Cited by 4

Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)Preprint

Leung, N., Cheng, S. M. S., Cohen, C. A., Martín-Sánchez, M., Au, N. Y. M., Luk, L. L. H., Tsang, L. C. H., Kwan, K. K. H., Chaothai, S., Fung, L. W. C., et al. (2022) · medRxiv · doi:10.1101/2022.08.25.22279158 · Cited by 4

Does side effects of COVID-19 vaccination include changes in menstrual cycle or its associated pre- and post-menstrual symptoms in reproductive-age women: A Multi-centric Observational study in India.Preprint

Kumar, N., Gagane, N., Mahopatra, I., Rukadikar, C. A., Sharmila, V., Pushpalatha, K., Eerike, M., Santhoshi, G., Samantaray, S. R., Seth, S., et al. (2023) · doi:10.22541/au.167368560.01551482/v1 · Cited by 4

The Lancet Commission on diagnostics: What it means for Singapore

Kuo, B. J., Busmanis, I. A., Tan, B. P., Tan, P. H., Teoh, W. C., & Tan, B. S. (2022) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.202242 · Cited by 3

B-Cell Responses to Sars-Cov-2 mRNA Vaccines

Kardava, L., Buckner, C. M., & Moir, S. L. (2022) · Pathogens and Immunity · doi:10.20411/pai.v7i2.550 · Cited by 3

Prevalence and factors associated with COVID-19 vaccine hesitancy among adults in Ghana: a population-based cross-sectional study in the Volta Region

Frempong, C. S., Tarkang, E. E., Amu, H., Gborglah, M., Salu, S., & Otoo, D. M. (2024) · Discover Public Health · doi:10.1186/s12982-024-00236-4 · Cited by 3

Rapid development of a registry to accelerate COVID-19 vaccine clinical trials

Abernethy, N. F., McCloskey, K., Trahey, M., Rinn, L., Broder, G. B., Andrasik, M. P., Laborde, R. R., McGhan, D., Spendolini, S., Marimuthu, S., et al. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01666-3 · Cited by 3

A statistical look at the COVID-19 vaccine development and vaccine policies

Apio, C., Han, K., Heo, G., & Park, T. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1048062 · Cited by 3

A vacina no Instagram: estudo das emoções expressas no contexto brasileiro

de Oliveira, G. F., Massarani, L., de Oliveira, T. M., Scalfi, G., & dos Santos, M. A. (2023) · Revista Mediterránea de Comunicación · doi:10.14198/medcom.24190 · Cited by 3

A Critical Assessment of COVID-19 Genomic Vaccines

Sabbah, D. A., Hajjo, R., & Sunoqrot, S. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230825094341 · Cited by 4

The safety of co-administration of Bacille Calmette-Guérin (BCG) and influenza vaccines

Villanueva, P., Wadia, U. D., Crawford, N. W., Messina, N. L., Kollmann, T. R., Lucas, M., Manning, L. A., Richmond, P., Pittet, L. F., & Curtis, N. C. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268042 · Cited by 3

The First Approved COVID-19 Vaccines: The Road to Cancer Vaccines

Saldanha, L., & Vale, N. (2022) · International Journal of Translational Medicine · doi:10.3390/ijtm2030025 · Cited by 3

COVID-19 Vaccines - Current State and Perspectives

Abdurakhmonov, I. Y. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101006 · Cited by 4

Gaps in vaccine clinical trials in Africa: A mixed scoping review and bibliometric analysis before, during, and post- COVID-19 pandemic

Uthman, O. A., Katoto, P. D., Anjorin, S., Marais, T., Amiche, A., & Nachega, J. B. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2481802 · Cited by 2

Heart Failure Readmission Risk Factors: A Modified Delphi Panel Study

Wiebe, N., Eastwood, C. A., Lee, S., Martin, E. A., Walker, R. L., Leung, A. A. C., Howlett, J. G., & Quan, H. (2025) · CJC Open · doi:10.1016/j.cjco.2025.09.001 · Cited by 2

The role of misinformation in COVID-19 vaccine hesitancy in low- & middle-income countries

Sarnaik, A. Y., Khan, Z. U., Rajeswaran, T., Majoe, A., Zeng, J., Ponrajah, L., Kastura, Z., Iftikhar, L., Islam, M. A., Basharat, N., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128595 · Cited by 2

A one-year follow-up study on dynamic changes of leukocyte subsets and virus-specific antibodies of patients with COVID-19 in Sichuan, China

Xu, R.-J., Zhao, B.-N., Lan, L.-J., Liu, Y.-L., Li, Y.-L., Jiang, L.-S., & Dai, S.-P. (2022) · International Journal of Medical Sciences · doi:10.7150/ijms.71286 · Cited by 1

Changes In the Menstrual Cycle Among the Covid-19 Vaccinated Women in The Eastern Province of Saudi Arabia: A Cross-Sectional Survey, 2022

Almousa, I. (2022) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2022.256581 · Cited by 2

Basic sciences in higher education, and teaching approaches in the context of 21st-century advances: Time for a change?

Maarman, G. J. (2023) · South African Journal of Higher Education · doi:10.20853/37-2-5016 · Cited by 2

Bridging the Gap: Can COVID-19 Research Help Combat African Swine Fever?

Pakotiprapha, D., Kuhaudomlarp, S., Tinikul, R., & Chanarat, S. (2023) · Viruses · doi:10.3390/v15091925 · Cited by 3

Side effects following administration of the Gam-COVID-Vac in Montenegro

Dabanović, V. (2023) · Russian Journal of Infection and Immunity · doi:10.15789/2220-7619-sef-15628 · Cited by 2

ERS International Congress 2023: highlights from the Paediatrics Assembly

Vijverberg, S. J. H., Kampouras, A., Büyükşahin, H. N., Makrinioti, H., Petrarca, L., Schmidt, M., Schreck, L. D., Urbantat, R. M., Beydon, N., Goutaki, M., et al. (2023) · ERJ Open Research · doi:10.1183/23120541.00853-2023 · Cited by 2

Party and play: Associations between US male sex workers' internet advertising characteristics and advertising chemsex to prospective clients

Jackson, K. J. (2024) · Drug and Alcohol Review · doi:10.1111/dar.13896 · Cited by 2

Health Economics of Vaccine Development and Distribution: Lessons from the COVID-19 Pandemic

Shah, S. S. (2024) · Premier journal of public health. · doi:10.70389/pjph.100015 · Cited by 2

The impact of public healthcare system on COVID-19 mortality rate in selected European and South Caucasian countries

Perone, G. (2025) · Eurasian economic review : · doi:10.1007/s40822-025-00310-5 · Cited by 2

Predicting immune protection against outcomes of infectious disease from population-level effectiveness data with application to COVID-19

Hao, T., RYAN, G. E., Lydeamore, M., Cromer, D., Wood, J. G., McVernon, J., McCaw, J. M., Shearer, F. M., & Golding, N. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126987 · Cited by 3

Key success factors in clinical trial operation of the smallpox vaccine LC16m8 against mpox in Colombia

Tomotsugu, N., Amaya-Mahecha, M. J., Hamana, M., Bautista-Gonzalez, M. D. M., Gaitán‐Duarte, H., Cortés, J. A., Mine, S., Ainai, A., Castellanos, J. E., Tokita, D., et al. (2025) · Global Health & Medicine · doi:10.35772/ghm.2025.01017 · Cited by 2

Analysis of humoral and cellular immune activation up to 21 months after heterologous and homologous COVID-19 vaccination

Torre, D. L., Orlandi, C., Conti, I., Barocci, S., Carlotti, E., Magnani, M., Casabianca, A., & Stefanetti, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1579163 · Cited by 2

Drug Repurposing Techniques in Viral Diseases

Zhang, R., Oerlemans, R., Wang, C., Zhang, L., & Groves, M. R. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101443 · Cited by 2

India’s COVID-19 vaccination policy-an analysis of problem, politics and policy

Mathur, D. (2022) · International Journal of Health Governance · doi:10.1108/ijhg-10-2021-0107 · Cited by 2

A Review on Strategies for COVID-19 Vaccine Development and Regulatory Requirements

Kulkarni, R., Kallepalli, S. P., Dharia, S., Kamble, G., & Parvathaneni, M. (2023) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v13i1.5868 · Cited by 2

The OM-85 bacterial lysate: A new tool against SARS-CoV-2?

Pivniouk, V. I., & Vercelli, D. (2023) · Multidisciplinary Respiratory Medicine · doi:10.4081/mrm.2023.906 · Cited by 3

HIV vaccines: Lessons from basic research, clinical trials, and public policy

Saiz, A., & Farenhem, K. L. (2023) · MIT Science Policy Review · doi:10.38105/spr.0cg04tczoe · Cited by 2

Evaluation of Immune Response to Mucosal Immunization with an Oral Probiotic-Based Vaccine in Mice: Potential for Prime-Boost Immunization against SARS-CoV-2

Leontieva, G., Gupalova, T. V., Desheva, Y. A., Kramskaya, T. A., Bormotova, E., Koroleva, I. V., Kopteva, O. S., & Suvorov, A. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010215 · Cited by 2

Changing Views toward mRNA based Covid Vaccines in the Scientific Literature: 2020 - 2024

Thoene, M. A. (2024) · Polish Annals of Medicine · doi:10.29089/paom/189961 · Cited by 3

Gramicidin S and Melittin - Potential anti-viral therapeutic peptides to treat SARS-CoV-2 infectionPreprint

Ghalib, M., Parekh, Y., Banu, S., Ram, S., Nagaraj, R., Kumar, B. K., & Idris, M. M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.21.465254 · Cited by 2

Physical Activity and COVID-19 Vaccines

Gasmi, A., Nehaoua, A., Noor, S., Mujawdiya, P. K., & Bilstrom, D. (2023) · Springer eBooks · doi:10.1007/978-981-99-1802-7_5 · Cited by 1

Developer and Partnership Differences in COVID-19 and Other Infections: Insights from DNA Vaccines

Okuyama, R. (2024) · Journal of Market Access & Health Policy · doi:10.3390/jmahp12040025 · Cited by 1

Comprehensive analyses of immune activity in COVID-19-vaccinated idiopathic pulmonary fibrosis patients

Maciejewska-Radomska, A., Czernia, P., Piotrowska, M., Wajda, B., Słomiński, B., Romantowski, J., Sudoł, A., Dabrowska, M. E., Górska, L., Smiatacz, T., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1436491 · Cited by 1

State of the Art and Emerging Technologies in Vaccine Design for Respiratory Pathogens

Ridelfi, M., Pierleoni, G., Fonseca, V. Z. G., Batani, G., Rappuoli, R., & Sala, C. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2500-1878 · Cited by 1

Accelerated vaccine process development by orthogonal protein characterization

James, D. A., Szymkowicz, L., Yin, L., Shah, H., Leach, M., & Chicz, R. M. (2025) · Scientific Reports · doi:10.1038/s41598-025-96642-y · Cited by 2

Vaccine Development, Its Implementation and Price Setting: A Historical Perspective with Proposed Ways to Move Forward

Standaert, B. A., Topachevskyi, O., & Ethgen, O. (2025) · Journal of Market Access & Health Policy · doi:10.3390/jmahp13040050 · Cited by 1

Strengthening Urban Pandemic Preparedness: A Dual-Focused Machine Learning-Enhanced Spatial Evaluation of Pandemic Vulnerability Through Infection Risk and Vaccination Accessibility

Liu, D., Gilliland, J., Nakaya, T., Kan, Z., Nagata, S., & Huang, J. (2025) · Applied Spatial Analysis and Policy · doi:10.1007/s12061-025-09773-0 · Cited by 1

Virus-like particle display of the SARS-CoV-2 receptor-binding domain using a modular tag/catcher system enhances immunogenicity of a DNA vaccine in mice

Okholm, A. K., Fougeroux, C. E., Hagen, S. H., Paludan, S. R., Nielsen, M. A., de Jongh, W. A., & Sander, A. F. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.129117 · Cited by 1

Discovery to delivery in 100 days: RNA therapeutics & their role in future pandemic preparedness

Humphries, T. (2022) · Vaccine Insights · doi:10.18609/vac.2022.38 · Cited by 1

The Vices and Virtues of Instrumentalized Knowledge

Siegmann, J., & Grayot, J. D. (2023) · Philosophies · doi:10.3390/philosophies8050084 · Cited by 1

Non-analytic behaviour in large-deviations of the susceptible-infected-recovered model under the influence of lockdowns

Mulholland, L. P., Feld, Y., & Hartmann, A. K. (2023) · New Journal of Physics · doi:10.1088/1367-2630/ad0991 · Cited by 1

Bilateral Sequential Abducens Nerve Palsy After Pfizer-BioNTech COVID-19 Vaccine (BNT162b2): A Case Report and Literature Review

Albattah, M. F., Al‐Hayk, K., Albattah, M., & Alshrouf, M. A. (2024) · Cureus · doi:10.7759/cureus.51682 · Cited by 1

Mammalian Antigen Display for Pandemic Countermeasures

Quezada, A., Annapareddy, A., Javanmardi, K., Cooper, J., & Finkelstein, I. J. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3666-4_12 · Cited by 1

COVID-19 in Older Adults

Clar, M., Walker, A., & Solomon, P. (2024) · Springer eBooks · doi:10.1007/978-3-030-74720-6_126 · Cited by 1

College leadership decisions and experiences during the COVID-19 pandemic: an elite interview study

Dutta, T., & Agley, J. D. (2024) · Journal of American College Health · doi:10.1080/07448481.2024.2328139 · Cited by 1

Monitoring Oxford-AstraZeneca COVID-19 vaccine Side Effects in Faridpur, Bangladesh: A Prospective Study

Arif, K. M., Biswas, R., Islam, M. M. S. U., & Rahman, A. A. (2024) · Bangabandhu Sheikh Mujib Medical College Journal · doi:10.3329/bsmmcj.v3i1.71916 · Cited by 1

DARCVAA: A Deep Neural Networks Based Framework for Detecting Adverse Reactions of COVID-19 Vaccines and Association Analysis

Ngamwal, S., Yogita, Y., Pal, V., & Verma, A. (2024) · SN Computer Science · doi:10.1007/s42979-024-02947-6 · Cited by 1

Safety pharmacology of human endogenous retrovirus-enveloped baculoviral DNA vaccines against SARS-CoV-2 in Sprague-Dawley rats and beagle dogs

Park, S., Seo, J., Han, K.-H., Lee, B., Lee, C., Kim, Y. B., Ko, K., & Kim, Y. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100545 · Cited by 1

Controvérsias sobre as vacinas e a vacinação contra COVID-19 no meio jornalístico

Gonçalves, B. A., Itagyba, R. F., Matos, C. C. D. S. A., & Couto, M. T. (2025) · Ciência & Saúde Coletiva · doi:10.1590/1413-81232025305.14472023 · Cited by 1

Accelerating clinical trial development in vaccinology: COVID-19 and beyond

Corey, L., & Miner, M. D. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102206 · Cited by 17

Effect of coronavirus disease 2019 on the vaccine development paradigm

Okay, S. (2023) · Exploration of Immunology · doi:10.37349/ei.2023.00111 · Cited by 5

How New Models Of Vaccine Development For COVID-19 Have Helped Address An Epic Public Health Crisis

Bloom, D. E., Cadarette, D., Ferranna, M., Hyer, R. N., & Tortorice, D. L. (2021) · Health Affairs · doi:10.1377/hlthaff.2020.02012 · Cited by 68

Super-rapid race for saving lives by developing COVID-19 vaccines

Uttarilli, A., Amalakanti, S., Kommoju, P.-R., Sharma, S., Goyal, P., Manjunath, G. K., Upadhayay, V., Parveen, A., Tandon, R., Prasad, K. S., et al. (2021) · Berichte aus der medizinischen Informatik und Bioinformatik/Journal of integrative bioinformatics · doi:10.1515/jib-2021-0002 · Cited by 31

Looking beyond the origin of SARS-CoV-2: Significant strategic aspects during the five-year journey of COVID-19 vaccine development

Chakraborty, C., Lo, Y.-H., Bhattacharya, M., Das, A., & Wen, Z. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102527 · Cited by 8